Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2026-09-10 21:17:30 ET · period of report 2026-09-08 · accession 0001104659-26-106831 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-10 21:17 | 2026-09-08+ | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $21.58 | +125.0K | 530.2K | +31% | +$2.70M |
| DMT | 2026-09-10 21:17 | 2026-09-08+ | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | S - Sale+OE | $145.92 | -125.0K | 523.0K | -19% | -$18.24M |
| DMT | 2026-09-10 21:17 | 2026-09-08+ | PTGX | PATEL DINESH V PH D | Pres, CEO, Dir | M - OptEx | $0.00 | -125.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-08 | M | A | 54,174 | $21.58 | 577,142 | D | — | — | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| 2 | Common | Common Stock | 2026-09-08 | S | D | 54,174 | $145.87 | 522,968 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.00 to $147.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-09-09 | M | A | 63,548 | $21.58 | 586,516 | D | — | — | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| 4 | Common | Common Stock | 2026-09-09 | S | D | 63,548 | $146.18 | 522,968 | D | — | — | (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $144.49 to $151.27. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2026-09-10 | M | A | 7,278 | $21.58 | 530,246 | D | — | — | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| 6 | Common | Common Stock | 2026-09-10 | S | D | 7,278 | $144.10 | 522,968 | D | — | — | (F4) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $142.51 to $145.19. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 7 | Derivative | Stock Option (right to buy) | 2026-09-08 | M | D | 54,174 | $0.00 | 70,826 | D | $21.58 · — to 2026-10-11 | 54,174 Common Stock | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| 8 | Derivative | Stock Option (right to buy) | 2026-09-09 | M | D | 63,548 | $0.00 | 7,278 | D | $21.58 · — to 2026-10-11 | 63,548 Common Stock | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |
| 9 | Derivative | Stock Option (right to buy) | 2026-09-10 | M | D | 7,278 | $0.00 | 0 | D | $21.58 · — to 2026-10-11 | 7,278 Common Stock | (F1) The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options. |